This is not the latest version of this item. The latest version can be found here.
Antibody Subclass and Glycosylation Shift Following Effective TB Treatment
Name
fimmu-12-679973.pdf
Description
Published version
Size
2.04 MB
Format
Adobe PDF
Checksum (MD5)
50170f9ec18be5f3e7320032cbb54817
Author(s)
Grace, Patricia S
Dolatshahi, Sepideh
Lu, Lenette L
Cain, Adam
Palmieri, Fabrizio
Petrone, Linda
Fortune, Sarah M
Ottenhoff, Tom HM
Lauffenburger, Douglas A
Goletti, Delia
Date Issued
2021
Journal
Frontiers in Immunology
Publisher
Frontiers Media SA
Version
Final published version
Abstract
With an estimated 25% of the global population infected with Mycobacterium tuberculosis (Mtb), tuberculosis (TB) remains a leading cause of death by infectious diseases. Humoral immunity following TB treatment is largely uncharacterized, and antibody profiling could provide insights into disease resolution. Here we focused on the distinctive TB-specific serum antibody features in active TB disease (ATB) and compared them with latent TB infection (LTBI) or treated ATB (txATB). As expected, di-galactosylated glycan structures (lacking sialic acid) found on IgG-Fc differentiated LTBI from ATB, but also discriminated txATB from ATB. Moreover, TB-specific IgG4 emerged as a novel antibody feature that correlated with active disease, elevated in ATB, but significantly diminished after therapy. These findings highlight 2 novel TB-specific antibody changes that track with the resolution of TB and may provide key insights to guide TB therapy.
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
10.3389/fimmu.2021.679973
